Clonal hematopoiesis

Association of Clonal Hematopoiesis With Silent Brain Lesions and Cognitive Decline in Patients With Atrial Fibrillation: An Integrative Review

By MedXY 08/24/2026

Clonal hematopoiesis (CHIP) significantly associates with increased silent brain lesions and progressive cognitive decline in atrial fibrillation patients, highlighting a novel neurovascular risk factor with implications for patient management and future research.

Clinical Updates Dentistry news

Bridging Periodontitis and Clonal Hematopoiesis: Implications for Solid Tumor Metastasis, Clinical Trial Design, and Microbiome Dynamics

By MedXY 07/24/2026

This review synthesizes evidence linking periodontitis-induced inflammation with clonal hematopoiesis, exploring implications for tumor metastasis, trial methodology, and microbiome-host crosstalk.

Hematology-Oncology news Ophthalmology

Synergistic Impact of Clonal Hematopoiesis and Genetic Predisposition on Age-Related Macular Degeneration Risk: Insights from a Large UK Biobank Cohort

By MedXY 07/11/2026

This cohort study reveals that clonal hematopoiesis of indeterminate potential (CHIP) independently increases age-related macular degeneration (AMD) risk, with amplified effects when combined with high genetic susceptibility, especially in older adults.

Hematology-Oncology news Oncology

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

By MedXY 05/09/2026

A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast cancer.

Cardiology Hematology-Oncology news

Colchicine May Curb the Expansion of Pro-Inflammatory Clonal Hematopoiesis: Insights From the LoDoCo2 Substudy

By MedXY 01/17/2026

A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing the proliferation of high-risk inflammatory clones.

Cardiology news

Large Clonal Hematopoiesis Clones Drive Myocardial Infarction Risk in People With HIV

By MedXY 01/07/2026

Data from the REPRIEVE trial indicates that while general clonal hematopoiesis is common in people with HIV, only large clones (VAF ≥10%) significantly elevate the risk for myocardial infarction and revascularization, independent of traditional risk factors and statin therapy.

Cardiology news Pathology & Lab Medicine

Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)

By MedXY 12/03/2025

A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discrimination (C=0.80) and reclassification.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Clinical Updates news

Personalized Low-Dose Aspirin Use for Cancer Prevention in Older Adults

By MedXY 09/25/2025

A secondary analysis of the ASPREE trial reveals low-dose aspirin’s heterogeneous effects on cancer prevention in older adults, highlighting clonal hematopoiesis of indeterminate potential (CHIP) as a key predictor for benefit.

Cardiology news Specialties

Clonal Hematopoiesis as a Novel Risk Factor for Myocarditis and Pericarditis: Insights from the UK Biobank

By MedXY 08/31/2025

Clonal hematopoiesis of indeterminate potential (CHIP) is linked to a significantly increased risk of new-onset myocarditis and pericarditis, especially involving DNMT3A and TET2 mutations, highlighting a potential target for preventing inflammatory heart diseases.

Allergy & Immunology Hematology-Oncology Specialties

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

By MedXY 08/29/2025

Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for prophylactic strategies.